CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 108 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $874,143 | -56.1% | 58,628 | -67.7% | 0.00% | – |
| Q2 2023 | $1,989,823 | -56.6% | 181,719 | -65.4% | 0.00% | – |
| Q1 2023 | $4,584,043 | +577.9% | 525,693 | +387.5% | 0.00% | – |
| Q4 2022 | $676,169 | +165.2% | 107,842 | +48.2% | 0.00% | – |
| Q3 2022 | $255,000 | -30.1% | 72,776 | -41.2% | 0.00% | – |
| Q2 2022 | $365,000 | +58.0% | 123,809 | +66.2% | 0.00% | – |
| Q1 2022 | $231,000 | -20.9% | 74,476 | -13.9% | 0.00% | – |
| Q4 2021 | $292,000 | -24.0% | 86,465 | -17.8% | 0.00% | – |
| Q3 2021 | $384,000 | -3.0% | 105,187 | +15.9% | 0.00% | – |
| Q2 2021 | $396,000 | -23.0% | 90,747 | -19.8% | 0.00% | – |
| Q1 2021 | $514,000 | +84.2% | 113,201 | +133.3% | 0.00% | – |
| Q4 2020 | $279,000 | +304.3% | 48,517 | +406.2% | 0.00% | – |
| Q3 2020 | $69,000 | -94.0% | 9,584 | -97.1% | 0.00% | – |
| Q2 2020 | $1,159,000 | +109.6% | 332,088 | -11.3% | 0.00% | – |
| Q1 2020 | $553,000 | +360.8% | 374,258 | +509.6% | 0.00% | – |
| Q4 2019 | $120,000 | -89.2% | 61,398 | -71.8% | 0.00% | – |
| Q3 2019 | $1,115,000 | -31.6% | 217,631 | -4.4% | 0.00% | – |
| Q2 2019 | $1,630,000 | -35.4% | 227,748 | +19.9% | 0.00% | – |
| Q1 2019 | $2,522,000 | +95.4% | 189,886 | +15.6% | 0.00% | – |
| Q4 2018 | $1,291,000 | -27.9% | 164,192 | +1.5% | 0.00% | – |
| Q3 2018 | $1,791,000 | +1267.2% | 161,714 | +1549.8% | 0.00% | – |
| Q2 2018 | $131,000 | -33.2% | 9,802 | -34.9% | 0.00% | – |
| Q1 2018 | $196,000 | – | 15,067 | +1506600.0% | 0.00% | – |
| Q4 2016 | $0 | -100.0% | 1 | -99.8% | 0.00% | – |
| Q3 2016 | $1,000 | – | 415 | +446.1% | 0.00% | – |
| Q2 2016 | $0 | -100.0% | 76 | -96.5% | 0.00% | – |
| Q1 2016 | $3,000 | -25.0% | 2,200 | 0.0% | 0.00% | – |
| Q4 2015 | $4,000 | 0.0% | 2,200 | 0.0% | 0.00% | – |
| Q3 2015 | $4,000 | -33.3% | 2,200 | 0.0% | 0.00% | – |
| Q2 2015 | $6,000 | – | 2,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |